SURMOUNT-1: How a Dual GIP/GLP-1 Peptide Delivered Up to Roughly 21% Weight Loss

Before retatrutide, the peptide that reset expectations for how much weight a medicine could achieve was tirzepatide. SURMOUNT-1, published in the New England Journal of Medicine in 2022 by Ania M. Jastreboff and colleagues, tested it in people with obesity who did not have diabetes and reported average reductions in body weight approaching a fifth or more at the higher doses. It was the pivotal obesity trial for a drug that combines two hormone actions in a single molecule.

Tirzepatide is a dual agonist: one peptide that activates both the GIP and GLP-1 receptors. GLP-1 receptor agonists were already established for glucose control and weight, and adding GIP-receptor activity was hypothesized to enhance metabolic effects. Tirzepatide had earlier been developed for type 2 diabetes, and SURMOUNT-1 was designed to quantify its effect on body weight specifically in people with obesity.

The trial randomized 2,539 adults who had obesity, or overweight with at least one weight-related complication, while excluding people with diabetes. Participants received once-weekly subcutaneous tirzepatide at 5, 10, or 15 mg, or placebo, over 72 weeks that included a 20-week dose-escalation phase. All groups also received lifestyle counseling. The co-primary endpoints were the percentage change in body weight and the proportion of participants achieving at least a 5% reduction.

At 72 weeks, the mean change in body weight was -15.0% with 5 mg, -19.5% with 10 mg, and -20.9% with 15 mg, compared with -3.1% for placebo. A complementary analysis restricted to participants who adhered to treatment estimated reductions of up to 22.5% at the 15-mg dose. The proportion of participants reaching at least 5% weight loss was 85%, 89%, and 91% across the tirzepatide doses, versus 35% for placebo.

Large fractions of participants also crossed higher thresholds, with many on the top doses losing at least 15% or 20% of their body weight, categories rarely reached with earlier weight-loss pharmacotherapy. Reported body-composition data indicated that fat mass fell proportionally more than lean mass. Cardiometabolic risk markers, including waist circumference, blood pressure, and lipid measures, improved as secondary endpoints.

As with other incretin-based drugs, the most common adverse events were gastrointestinal, mainly nausea, diarrhea, constipation, and vomiting. Most were mild to moderate and concentrated during the dose-escalation period, and a minority of participants discontinued because of adverse events. The trial was not designed to measure long-term cardiovascular outcomes; that question is addressed by separate, dedicated studies.

SURMOUNT-1 measured weight and metabolic markers over 72 weeks, which is substantial but still finite. It did not establish what happens after treatment stops, and weight regain following discontinuation has been reported for this drug class in other analyses. As a weight-focused efficacy trial, it used body weight as its central endpoint, a well-validated surrogate that is nonetheless distinct from a directly measured reduction in illness or death.

Tirzepatide has since been approved for chronic weight management in multiple jurisdictions, marketed for obesity under one brand name and for type 2 diabetes under another, so unlike some compounds discussed on this site it is a regulated medicine rather than an experimental one. SURMOUNT-1 remains the foundational efficacy evidence behind that use. The results are best read as a rigorous demonstration of average effect in a defined trial population, not as a recommendation or a dosing guide for any individual.